Metabolic syndrome and mental illness
- PMID: 18041878
Metabolic syndrome and mental illness
Erratum in
- Am J Manag Care. 2008 Feb;14(2):76
Abstract
Patients with mental illnesses such as schizophrenia and bipolar disorder have an increased prevalence of metabolic syndrome and its components, risk factors for cardiovascular disease and type 2 diabetes. Although the prevalence of obesity and other risk factors such as hyperglycemia are increasing in the general population, patients with major mental illnesses have an increased prevalence of overweight and obesity, hyperglycemia, dyslipidemia, hypertension, and smoking, and substantially greater mortality, compared with the general population. Persons with major mental disorders lose 25 to 30 years of potential life in comparison with the general population, primarily due to premature cardiovascular mortality. The causes of increased cardiometabolic risk in this population can include nondisease-related factors such as poverty and reduced access to medical care, as well as adverse metabolic side effects associated with psychotropic medications, such as antipsychotic drugs. Individual antipsychotic medications are associated with well-defined risks of weight gain and related risks for adverse changes in glucose and lipid metabolism. Based on the medical risk profile of persons with major mental illnesses, and the evidence that certain medications can contribute to increased risk, screening and regular monitoring of metabolic parameters such as weight (body mass index), waist circumference, plasma glucose and lipids, and blood pressure are recommended to manage risk in this population. Treatment decisions should incorporate information about medical risk factors in general and cardiometabolic risk in particular. In addition to the implications for individual clinicians, the problem of disparity in meeting healthcare needs for persons with mental illness in comparison with the general population has become an important public policy concern, with recent recommendations from the National Association of State Mental Health Program Directors and the Institute of Medicine. This article provides an overview of cardiometabolic risk in patients with major mental illness and describes steps for risk reduction.
Similar articles
-
[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9. Encephale. 2009. PMID: 19748369 French.
-
Antipsychotic medications: metabolic and cardiovascular risk.J Clin Psychiatry. 2007;68 Suppl 4:8-13. J Clin Psychiatry. 2007. PMID: 17539694 Review.
-
Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses.J Clin Psychiatry. 2009;70 Suppl 3:30-6. doi: 10.4088/JCP.7075su1c.05. J Clin Psychiatry. 2009. PMID: 19570499 Review.
-
Metabolic syndrome: epidemiology and consequences.J Clin Psychiatry. 2004;65 Suppl 18:3-12. J Clin Psychiatry. 2004. PMID: 15600380 Review.
-
Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.J Clin Psychiatry. 2007;68 Suppl 1:20-7. J Clin Psychiatry. 2007. PMID: 17286524 Review.
Cited by
-
Can anti-inflammatory medications improve symptoms and reduce mortality in schizophrenia?Curr Psychiatr. 2016 May;15(5):52-57. Epub 2016 Apr 25. Curr Psychiatr. 2016. PMID: 27274712 Free PMC article. No abstract available.
-
Metabolomic Profiling of Post-Mortem Brain Reveals Changes in Amino Acid and Glucose Metabolism in Mental Illness Compared with Controls.Comput Struct Biotechnol J. 2016 Feb 26;14:106-16. doi: 10.1016/j.csbj.2016.02.003. eCollection 2016. Comput Struct Biotechnol J. 2016. PMID: 27076878 Free PMC article.
-
Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration.BMC Psychiatry. 2009 Dec 18;9:80. doi: 10.1186/1471-244X-9-80. BMC Psychiatry. 2009. PMID: 20021664 Free PMC article.
-
Sex difference in the association of body mass index and BDNF levels in Chinese patients with chronic schizophrenia.Psychopharmacology (Berl). 2019 Feb;236(2):753-762. doi: 10.1007/s00213-018-5107-1. Epub 2018 Nov 19. Psychopharmacology (Berl). 2019. PMID: 30456540
-
An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder.Neuropsychiatr Dis Treat. 2021 Sep 9;17:2885-2904. doi: 10.2147/NDT.S313840. eCollection 2021. Neuropsychiatr Dis Treat. 2021. PMID: 34526769 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical